.Attributes Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a typical follow-up of 11 months, patients along with metastatic gastrointestinal growths who got biomarker-matched treatments based on distributing cyst DNA profiling showed a more significant clinical perk than those getting unrivaled therapy.